SEARCH FOR REPRODUCIBLE BIOMARKERS FOR THE DIAGNOSIS OF PREECLAMPSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents data as an analytical literature review on recent trials in order to search for biomarkers to diagnose preeclampsia, including at the early stages of pathology development in the absence of clinical manifestations. It gives the panels of markers, which have been obtained by both biochemical and mass spectrometric methods and included proteins, peptides, glycoproteins, and metabolites in serum/plasma and urine. Among a lot of these biomarkers, there are separately substances (groups of substances) that have undergone trials on a large number (more than 200) of patients, which have shown their high sensitivity and specificity, good reproducibility, as well as the possibility of their use to assess the risk of preeclampsia at the early stages of a pathological condition. It is also concluded that the additional use of Doppler ultrasound studies enhances the diagnostic accuracy of the pathology, by increasing not only the sensitivity of the marker panel, but also the specificity of the test.

Full Text

Restricted Access

About the authors

N. L STARODUBTSEVA

Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences; N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences; Moscow Institute of Physics and Technology (State University)

Email: snl_1985@yandex.ru

A. A POPOV

Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences; Moscow Institute of Physics and Technology (State University)

Email: hexapole@gmail.com

E. N NIKOLAYEV

N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences

Email: ennikolaev@rambler.ru

T. Yu IVANETS

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: t_ivanets@oparina4.ru

M. L ALEKSEYEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

N. S LOGINOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

A. V NIKOLAEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

O. V VAVINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

G. T SUKHIKH

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

References

  1. Say L., Inoue M., Mills S., Suzuki E. Maternal mortality in 2005. Geneva: World Health Organization; 2005.
  2. McDonald S.D., Malinowski A., Zhou Q., Yusuf S., Devereaux P.J. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am. Heart J. 2008; 156(5): 918—30.
  3. WHO/OMS. Programme of Work 2004—2008 of Department of Reproductive Health and Research. Geneva; 2003.
  4. Meads C.A., Cnossen J.S., Meher S., Juarez-Garcia A., ter Riet G., Duley L. et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol. Assess. 2008; 12(6): iii—iv; 1—270.
  5. Thangaratinam S., Coomarasamy A., Sharp S., O’Mahony F., O’Brien S., Ismail K.M., Khan K.S. Tests for predicting complications of pre-eclampsia: a protocol for systematic reviews. BMC Pregnancy Childbirth. 2008; 8: 38.
  6. Brown M.A., Lindheimer M.D., de Swiet M., Van Assche A., Moutquin J.M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens. Pregnancy. 2001; 20(1): IX—XIV.
  7. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am. J. Obstet. Gynecol. 2006; 195: 255—9.
  8. Roberts J.M., Hubel C.A. The two stage model of preeclampsia: variations on the theme. Placenta. 2009; 30( Suppl. A): 32—7.
  9. Zhou Y., Fisher S.J., Janatpour M., Genbacev O., Dejana E., Wheelock M., Damsky C.H. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J. Clin. Invest. 1997; 99: 2139—51.
  10. Quenby S., Farquharson R. Uterine natural killer cells, implantation failure and recurrent miscarriage. Reprod. Biomed. Online. 2006; 13: 24—8.
  11. Kharfi A., Giguere Y., Sapin V., Masse J., Dastugue B., Forest J.C. Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines. Clin. Biochem. 2003; 36: 323—31.
  12. Janatpour M.J., Utset M.F., Cross J.C., Rossant J., Dong J., Israel M.A., Fisher S.J. A repertoire of differentially expressed transcription factors that offers insight into mechanisms of human cytotrophoblast differentiation. Dev. Genet. 1999; 25: 146—57.
  13. Paulding W.R., Czyzyk-Krzeska M.F. Hypoxia-induced regulation of mRNA stability. Adv. Exp. Med. Biol. 2000; 475: 111—20.
  14. Crocker I.P., Cooper S., Ong S.C., Baker P.N. Differences in apoptotic susceptibility of cytotrophoblast and syncytio-trophoblast in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am. J. Pathol. 2003; 162: 637—43.
  15. Koopmans C.M., van Pampus M.G., Groen H., Aarnoudse J.G., van den Berg P.P., Mol B.W. Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 146(1): 8—14.
  16. Benyo D., Smarason A., Redman C., Sims C., Conrad K. Expression of inflammatory cytokines in placentas from women with preeclampsia. J. Clin. Endocrinol. Metab. 2001; 86: 2505—12.
  17. Page N.M., Woods R.J., Gardiner S.M., Lomthaisong K., Gladwell R.T., Butlin D.J. et al. Excessive placental secretion of neurokinin B during the third trimester causes preeclampsia. Nature. 2000; 405 (6788): 797—800.
  18. Savvidou M., Hingorani A., Tsikas D., Frolich J., Vallance P., Nicolaides K. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361: 1511—7.
  19. Kim Y., Lee D., Jeong D., Sung M., Kim K. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat. Diagn. 2009; 29:464—70.
  20. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 2004; 95: 884—91.
  21. Chaiworapongsa T., Romero R., Kim Y.M., Kim G.J., Kim M.R., Espinoza J. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern. Fetal Neonatal Med. 2005; 17(1): 3—18.
  22. Herse F., Verlohren S., Wenzel K., Pape J., Muller D.N., Modrow S. et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009; 53(2): 393—8.
  23. Wikstrom A.K., Larsson A., Eriksson U.J., Nash P., Norden-Lindeberg S., Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 2007; 109: 1368—74.
  24. Kenny L.C., Broadhurst D.I., Dunn W., Brown M., North R.A., McCowan L. et al. Screening for Pregnancy Endpoints Consortium. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010; 56(4): 741—9.
  25. Smith G.C., Crossley J.A., Aitken D.A., Jenkins N., Lyall F., Cameron A.D. et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet. Gynecol. 2007; 109(6): 1316—24.
  26. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350(7):672—83.
  27. Polliotti B.M., Fry A.G., Saller D.N., Mooney R.A., Cox C., Miller R.K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet. Gynecol. 2003; 101(6): 1266—74.
  28. Ohkuchi A., Hirashima C., Suzuki H., Takahashi K., Yoshida M., Matsubara S., Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens. Res. 2010; 33(5): 422—7.
  29. Molvarec A., Szarka A., Walentin S., Beko G., Karádi I., Prohászka Z., Rigó J. Jr. Serum heat shock protein 70 levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in women with preeclampsia. Clin. Chim. Acta. 2011; 412(21-22): 1957— 62.
  30. Buhimschi I., Norwitz E.R., Funai E., Richman S., Guller S., Lockwood C.J., Buhimschi I.A. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 2005; 192(3): 734—41.
  31. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355(10): 992—1005.
  32. Romero R., Nien J.K., Espinoza J., Todem D., Fu W., Chung H. et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal Neonatal Med. 2008; 21(1): 9—23.
  33. Buhimschi C.M., Baumbusch M.A., Dulay A.T., Lee S., Wehrum M., Zhao G. et al. The role of urinary soluble endoglin in the diagnosis of preeclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. Br. J. Obstet. Gynaecol. 2010; 117(3): 321—30.
  34. D’Anna R., Baviera G., Corrado F., Crisafulli A., Ientile R., Buemi M., Squadrito F. Neurokinin B and nitric oxide plasma levels in pre-eclampsia and isolated intrauterine growth restriction. Br.J. Obstet. Gynaecol. 2004; 111(10): 1046—50.
  35. Li Z.M., Zhao Y., Chen Q., Zou L., Wang Z.H. Relationship between neurokinin B and endothelin-1 and hypertensive disorders complicating pregnancy. Zhonghua Fu Chan Ke Za Zhi. 2008; 43: 584—8.
  36. Walther Т., Wallukat G., Jank A., Bartel S., Schultheiss H.P., Faber R., Stepan H. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005; 46(6): 1275—9.
  37. Herse F., Verlohren S., Wenzel K., Pape J., Muller D.N., Modrow S. et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009; 53(2): 393—8.
  38. Banzola I., Farina A., Concu M., Sekizawa A., Purwosunu Y., Strada I. et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks’ gestation. Prenat. Diagn. 2007; 27(11): 1005—10.
  39. Chafetz I., Kuhnreich I., Sammar M., Tal Y., Gibor Y., Meiri H. et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am. J. Obstet. Gynecol. 2007; 197(1): 35; e1—7.
  40. Nicolaides K.H., Bindra R., Turan O.M., Chefetz I., Sammar M., Meiri H. et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol. 2006; 27(1): 13—7.
  41. Spencer K., Yu C.K., Savvidou M., Papageorghiou A.T., Nicolaides K.H. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 to 24 weeks’ gestation. Ultrasound Obstet. Gynecol. 2006; 27: 658—63.
  42. Rovere-Querini P., Antonacci S., Dell’Antonio G., Angeli A., Almirante G., Cin E.D. et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet. Gynecol. 2006; 108(1): 148—55.
  43. Levine R.J., Qian C., Leshane E.S., Yu K.F., England L.J., Schisterman E.F. et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am. J. Obstet. Gynecol. 2004; 190(3): 707—13.
  44. Spencer K., Cowans N.J., Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat. Diagn. 2008; 28: 212—6.
  45. Poon L.C., Chelemen T., Granvillano O., Pandeva I., Nicolaides K.H. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet. Gynecol. 2008; 112: 1082—90.
  46. Hu W., Wang Z., Wang H., Huang H., Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet. Gynecol. Scand. 2008; 87: 413—8.
  47. Zenna A.A., Zedan M., el-Salam G.E., el-Mashad A.I. Study of plasma adrenomedullin level in normal pregnancy and preeclampsia. Medscape J. Med. 2008; 10(2): 29.
  48. Poon L.C., Kametas N.A., Maiz N., Akolekar R., Nicolaides K.H. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009; 53: 812—8.
  49. Buhimschi I.A., Zhao G., Funai E.F., Harris N., Sasson I.E., Bernstein I.M. et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am. J. Obstet. Gynecol. 2008; 199(5): 551; e1—16.
  50. Park J., Cha D.H., Lee S.J., Kim Y.N., Kim Y.H., Kim K.P. Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp. Mol. Med. 2011; 43(7): 427—35.
  51. Liu C., Zhang N., Yu H., Chen Y., Liang Y., Deng H., Zhang Z. Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia. Placenta. 2011; 32(2): 168—174.
  52. Kenny L.C., Broadhurst D.I., Dunn W. et al. Screening for Pregnancy Endpoints Consortium. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010; 56(4): 741—9. 53.
  53. Odibo A.O., Goetzinger K.R., Odibo L., Cahill A.G., Macones G.A., Nelson D.M., Dietzen D.J. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat. Diagn. 2011; 31(10): 990—4.
  54. Anderssohn M., Maas L.M., Diemert A. Severely decreased activity of placental dimethylarginine dimethylaminohydrolase in pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 161(2): 152—6.
  55. Collino F., Bussolati B., Gerbaudo E., Marozio L., Pelissetto S., Benedetto C., Camussi G. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by glomerular endothelial cells. Am. J. Physiol. Renal Physiol. 2008; 294(5): F1185—94.
  56. Wang Y., Zhao S., Loyd S., Groome L.J. Increased urinary excretion of nephrin, podocalyxin, and pig-h3 in women with preeclampsia. Am. J. Physiol. Renal Physiol. 2012; 302(9): F1084—9.
  57. Son G.H., Kim J.H., Hwang J.H., Kim Y.H., Park Y.W., Kwon J.Y. Urinary excretion of nephrin in patients with severe preeclampsia. Urinary nephrin in preeclampsia. Hypertens. Pregnancy. 2011; 30(4): 408—13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies